DANBURY, Conn., Nov. 8, 2010 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following abstracts describing recent findings from the company's product development programs have been accepted for poster presentation at the Tenth Annual Diabetes Technology Meeting in Bethesda, MD, November 11 and 12, 2010:
"Characterization of Pharmacokinetics and Toleration of Three Variant Formulations of Linjeta"; presented by Dr. Frank Flacke, November 12
"A Stabilized Liquid Glucagon Formulation For Bi-hormonal Pump Use"; presented by Dr. Solomon Steiner, November 12
"A New Formulation of Insulin Glargine with an Extended Release Profile"; presented by Dr. Roderike Pohl, November 12
"'Smart' Basal Insulin Formulation That Releases Insulin in Response to Changing Blood Glucose Concentrations"; presented by Nandini Kashyap, November 11
The posters will be available on the company's website, www.biodel.com.
The Diabetes Technology Meeting focuses on the latest technological advances for people with diabetes. Its purpose is to bring together technology developers and users to facilitate the creation of new and cost-effective tools—including an artificial pancreas—to help people with diabetes. This year's meeting will include sessions on technologies for metabolic monitoring, biomarkers for early diagnosis of diabetes, the performance of closed-loop artificial pancreas systems and alternative delivery routes for insulin.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel™ technology, which reformulates existing FDA-approved peptide drugs. Linjeta™ is Biodel's most ad